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Aims Levels of circulating CD14highCD16+ monocytes increase in atherosclerotic patients and are predictive of future car-
diovascular events. Platelet activation has been identified as a crucial determinant in the acquisition of a CD16+ pheno-
type by classical CD14highCD162 cells. We tested the hypothesis that anti-platelet drugs modulate the phenotype of
circulating monocytes.
Methods
and results
Sixty healthy subjects undergoing influenza immunization were randomly assigned to either no treatment or anti-plate-
let therapy, namely aspirin 300 mg or 75 mg daily, or clopidogrel (300 mg loading dose followed by 75 mg), for 48 h
post-immunization (n ¼ 15/group). Monocyte subsets, high-sensitivity C-reactive protein, pro-inflammatory cytokines,
and P-selectin were measured at baseline and post-immunization. The CD14highCD16+ monocyte cell count rose by
67.3% [interquartile range (IQR): 35.7/169.2; P ¼ 0.0002 vs. baseline] in untreated participants. All anti-platelet regimes
counteracted expansion of this monocytic subpopulation. Although no statistical differences were noted among the
three treatments, aspirin 300 mg was the most efficacious compared with the untreated group (212.5% change
from baseline; IQR: 228.7/18.31; P ¼ 0.001 vs. untreated). Similarly, the rise in P-selectin (17%; IQR: 25.0/39.7;
P ¼ 0.03 vs. baseline) observed in untreated participants was abolished by all treatments, with aspirin 300 mg exerting
the strongest effect (230.7%; IQR: 258.4/20.03; P ¼ 0.007 vs. untreated). Changes in P-selectin levels directly cor-
related with changes in CD14highCD16+ cell count (r ¼ 0.5; P ¼ 0.0002). There was a similar increase among groups in
high-sensitivity C-reactive protein (P, 0.03 vs. baseline levels).
Conclusions Anti-platelet drugs exert an immunomodulatory action by counteracting CD14highCD16+ monocyte increase under
pro-inflammatory conditions, with this effect being dependent on the amplitude of P-selectin reduction.
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1. Introduction
Circulating human monocytes consist of a heterogeneous cell popula-
tion generally classified into three main subtypes: the ‘classical’
CD14highCD162, ‘intermediate’ CD14highCD16+, and ‘non-classical’
CD14lowCD16+ cells.1 The prevalence of these subpopulations in
the peripheral blood changes under pro-inflammatory conditions,
with an expansion of the ‘intermediate’ subset typically occurring in
the context of atherosclerosis-related inflammation.2 Although the func-
tional implications of such an event in terms of disease progression remain
elusive, a positive correlation between the level of CD14highCD16+
monocytes and the presence of subclinical atherosclerosis has been de-
monstrated.3 More importantly, intermediate monocytes have proved
to be an independent predictive factor for future cardiovascular events,4
and good correlation between their blood level and coronary plaque
vulnerability has been detected.5–8 This indicates that CD14highCD16+
cells may represent a novel biomarker of cardiovascular risk and a poten-
tial target for preventative therapeutic strategies.
In this respect, our previous work suggests that anti-platelet drugs
may have a modulatory action on the phenotype of circulating
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monocytes. Indeed, we have found that platelet activation is a key de-
terminant in the acquisition of a CD16+ profile by human monocytes.9
Furthermore, using ApoE2/2 mice, we have demonstrated the efficacy
of platelet inhibition in vivo, as achieved by either aspirin or clopidogrel
administration, in counteracting the blood monocytosis and expansion
of circulating Ly6Clow cells, i.e. the murine counterpart of CD16 mono-
cytes that accompany disease progression in this well-established ani-
mal model of atherosclerosis.10 In the current clinical study, we have
assessed the effect of anti-platelet drugs currently used in cardiovascu-
lar prophylaxis on the phenotype of circulating monocytes in healthy
human subjects. We have used the influenza immunization as an experi-
mental model of acute inflammation, in line with our previous report
showing an increase in the pool of circulating CD14highCD16+ cells
in response to vaccine administration,9 and also in keeping with other
researchers who have previously used immunizations, particularly the
seasonal influenza and Salmonella typhi immunizations, as stimuli in clin-
ical studies to generate mild, systemic inflammation and investigate car-
diovascular physiology.11– 13
2. Methods
2.1 Study design
Sixty healthy subjects were studied before and 48 h after receiving the sea-
sonal influenza immunization in agreement with our previously published
work.9 Subjects were recruited from workers employed by Guy’s and St
Thomas’ National Health Service Foundation Trust (GSTT) who attended
the Occupational Health Department requesting influenza immunization.
Recruitment criteria were as follows: age .18 years with no significant
past medical history and taking no regular prescribed, herbal, or
over-the-counter medications. None of the subjects had taken anti-platelet
or anti-inflammatory drugs in the preceding fortnight, and the cut-off value
for high-sensitivity C-reactive protein at baseline was 2 mg/L. Participants
were randomly assigned to receive either anti-platelet therapy or no treat-
ment, according to the following scheme:
Group 1 (aspirin 300, n ¼ 15): aspirin 300 mg once daily for 48 h follow-
ing immunization
Group 2 (aspirin 75, n ¼ 15): aspirin 75 mg once daily for 48 h following
immunization
Group 3 (clopidogrel, n ¼ 15): initial loading dose of clopidogrel 300 mg
orally following immunization, with a further dose of clopidogrel 75 mg
24 h later
Group 4 (untreated, n ¼ 15): no anti-platelet treatment given following
immunization
The first dose of the drug was administrated concomitantly to influenza
vaccination, and directly observed tablet taking was carried out by the
investigators.
The clinical study was reviewed and given favourable opinion by the
NRES London—Dulwich Research Ethics Committee (ref. number 13/
LO/1664) and registered on the UK Clinical Research Network Portfolio
(South London network study identification number 16644). All partici-
pants gave informed consent. The study was performed conforming to
the Declaration of Helsinki.
2.2 Influenza immunization
The 2014/15 National Health Service trivalent seasonal influenza immun-
ization, an inactivated (split virion) vaccination, specifically targeting ‘A/Cali-
fornia/7/2009 (H1N1)pdm09-like virus’, ‘A/Texas/50/2012 (H3N2)-like
virus’, and ‘B/Massachusetts/2/2012-like virus’, manufactured by Sanofi Pas-
teur MSD Limited, was administered via intramuscular injection into the
upper arm by a trained healthcare professional.
2.3 Blood collection
Venous blood samples were collected immediately prior to immunization
and again 48 h later. Samples were processed at ViaPath laboratory at
GSTT, London (UK) for measurement of triglycerides, total cholesterol,
low-density lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, and HbA1c at baseline only. Full blood count and high-
sensitivity C-reactive protein was measured at baseline and 48 h post-
immunization using a Dade Behring BN II automated analyser to perform
an assay utilizing polystyrene particles coated with monoclonal antibody
and fixed-time kinetic nephelometric measurements.14 Additional samples
were obtained at both time points for whole blood flow cytometry to char-
acterize monocyte phenotypes (as detailed in the following paragraphs), for
serum collection to measure pro-inflammatory cytokines and plasma cit-
rate for P-selectin assessment. Blood sampling at baseline and post-
vaccination took place at the same time to exclude circadian variation.
2.4 Whole blood flow cytometry analysis
Monocyte characterization was performed accordingly with previously
published methods.9 Briefly, 100 mL whole blood collected in ethylenedia-
minetetraacetic acid (EDTA) vacutainer tubes was incubated with saturat-
ing concentrations of both R-phycoerythrin (PE)-mouse anti-human CD14
(M5E2 clone; BD Bioscience, UK) and fluorescein isothiocyanate (FITC)-
conjugated mouse anti-human CD16 (3G8 clone; BD Bioscience) for
20 min at 48C. Isotype antibodies were used as negative control. Following
erythrocyte lysis in BD FACS lysing solution (BD Bioscience), samples were
washed in phosphate buffered saline containing 0.2% bovine serum albumin
and 0.1% sodium azide, and then fixed in 1% paraformaldehyde. Immunos-
taining took place within an hour of the samples being obtained and data
were acquired using a BD FACSCalibur (BD Bioscience) flow cytometer.
A total of 100 000 events were acquired and post-acquisition analysis
was performed using FlowJo (version 10) software (Tree Star, Ashland,
OR, USA). Monocytes were identified on a forward (FSC) vs. side scatter
(SSC) plot and gated to analyse expression of CD14 and CD16 fluores-
cence, in order to distinguish the different subsets of monocytes, including
‘classical’ CD14highCD162, ‘intermediate’ CD14highCD16+ and ‘non-
classical’ CD14lowCD16+ cells. Percentage of each monocyte subset
over total monocytes was calculated and absolute numbers were obtained
based on full blood count. Every analysis was performed independently by
two blinded researchers. In a subgroup of 10 participants, repeated mea-
sures of monocyte subset cell count were carried out on two consecutive
measurements 2 days apart and before vaccine administration, in order to
assess variability in monocyte subset cell count in the absence of any inter-
vention (vaccination either in the presence or absence of pharmacological
treatment). Such an analysis showed inter-assay variation of,2% for all the
different monocytic subsets. Moreover, our gating strategy for monocyte
characterization (which was based on a FSC vs. SSC monocyte profile)
was directly compared with a flow cytometry methodology that also in-
cludes the pan-monocytic marker antibody, namely allopuricine-mouse
anti-human CD86, in the antibody panel.15 In this case, cells with a typical
monocytic FSC vs. SSC profile and positive to CD86 staining were gated to
analyse CD14 and CD16 expression. Prevalence of the different monocyte
subpopulations obtained with the two gating strategies was analysed on
SPSS (version 23) to calculate the intraclass correlation coefficient (ICC)
using an absolute agreement definition. The ICC was 0.961 (95% CI:
0.859–0.989; P, 0.0001), 0.924 (95% CI: 0.711–0.980; P, 0.0001), and
0.915 (95% CI: 0.695–0.977; P, 0.0001) for the classical, intermediate,
and non-classical subsets, respectively (Supplementary material online,
Figure S1). Moreover, in order to increase robustness of data in the analysis
of changes in the phenotype of circulating monocytes 48 h post-
immunization in the different groups, we also analysed the level of CD16
expression on monocytes using a normalized median fluorescence intensity
(nMFI) strategy, in agreement with previously published methods used to
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monitor changes in cell immunophenotype in repeated measures.16 A rep-
resentative analysis of flow cytometry data is shown in Figure 1.
2.5 Enzyme-linked immunosorbent assays and
luminex assay
Enzyme-linked immunosorbent assays (ELISAs) were carried out to meas-
ure plasma levels of P-selectin (BEK1189, Biospes, China) using commer-
cially available kits, as per manufacturer instructions. Inter-assay variability
was found to be ,5% for all the ELISA tests.
A custom-made magnetic Luminexw ultrasensitive cytokine multiplex as-
say (Life Technologies Corporation, UK) was performed to measure levels
of interleukin 1-b (IL-1b), interleukin-6 (IL-6), and tumour necrosis factor-
alpha (TNF-a) in serum. Manufacturer instructions were followed and
plates were analysed using a Luminex Flex Map 3Dw analyser.
2.6 Sample size calculation
The sample size population for the study was calculated in accordance with
previously published data that showed a standard deviation for CD16+
monocytes within a healthy population of 5%, with a difference in means
between pre- and post-immunization values of 7.5%.9 Assuming a minimum
detectable difference in means between the anti-platelet therapy and un-
treated groups at the end of the study of 4%; at power 0.9, and significance
level of 0.05, this yielded a sample size of 15 per group.
2.7 Statistical analysis
Statistical analyses were performed using SPSS (version 23) software. A
Shapiro–Wilk normality test was run for all variables measured in the
study. The effect of treatments on monocyte subtypes, inflammatory bio-
markers (high-sensitivity C-reactive protein and cytokines), and platelet ac-
tivation (soluble P-selectin), which were all found not to be normally
distributed, were compared using a non-parametric analysis of co-variance
(rank ANCOVA) with Bonferroni post hoc correction for multiple compari-
son analysis, using baseline values as a covariate. Baseline vs. post-
vaccination comparison of the analysed variables was also analysed within
each group by Wilcoxon matched-pairs signed-rank test. Associations be-
tween variables were assessed by a Spearman’s correlation analysis. A
P-value of ,0.05 was accepted as statistically significant. Data are ex-
pressed as the mean+ standard error of mean (SEM) or median and inter-
quartile ranges (IQR) for parametric or non-parametric variables,
respectively.
3. Results
3.1 Anti-platelet drugs do not influence
high-sensitivity C-reactive protein rise
post-immunization
General characteristics of the study population stratified across groups
are shown in Table 1. The influenza immunization induced an acute
Figure 1 Representative flow cytometry data. Dot plots representative of untreated (A) and treated (B) participants are shown. Expression of CD14 and
CD16 was analysed within the monocyte gated population identified on a FSC vs. SSC plot (A1 and B1, in black), enabling distinction of CD14highCD162
(black), CD14highCD16+ (red), and CD14lowCD16+ (blue) cells (the isotype control is in grey). Expression of CD16 and CD14 is shown in the ungated
population for completeness in the side panels A1 and B1, representing monocytes (black, CD14+), neutrophils (blue, CD142CD16high), and lymphocytes
(green, CD142CD16low, likely NK cells). Since significant differences between groups were observed in the prevalence and cell number of CD14highCD162
(black) and CD14highCD16+ (red) subsets, the level of CD16 expression was also specifically analysed within the CD14high population, using an nMFI strat-
egy. The histograms (C and D) show overlay of the baseline (empty histogram) and post-vaccination (filled histogram) intensity of fluorescence for CD16 of
the stained samples (red). Also shown are the fluorescence levels of the antibody isotype controls (in grey, with dotted histogram and filled histogram for
baseline and post-vaccination samples, respectively). The median fluorescence intensity (MFI) calculated in CD14high monocytes at baseline (pre) and post-
vaccination (post) was normalized by the MFI of the corresponding isotype control as indicated in the figure.
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inflammatory response as evidenced by an increase in baseline high-
sensitivity C-reactive protein post-vaccination in all groups (Figure 2).
None of the anti-platelet drugs modified the rise in high-sensitivity
C-reactive protein in response to vaccine administration (Figure 2).
There were no significant differences between post-vaccination and
baseline levels of pro-inflammatory cytokines in any of the groups
(Figure 2).
3.2 Expansion in the pool of intermediate
CD14highCD161monocytes in response to
influenza immunization is attenuated by
anti-platelet treatment
The baseline monocyte phenotype was similar among groups (Figure 3),
with a typical preponderance of the classical CD14highCD162 subtype
(median of 92.7% of total monocytes) over the intermediate
CD14highCD16+ (4.2%) and non-classical CD14lowCD16+ (3.2%) sub-
populations in all participants (Figure 3). While the total monocyte cell
count remained stable post-vaccination in the whole study population,
differences emerged among groups on the distribution of the different
subsets. Indeed, the untreated participants showed a significant in-
crease in both prevalence (from a median of 3.7 to 7.8% in median;
P ¼ 0.0002) and absolute number (from a median of 18.07 to 33.40
cells/mL; P ¼ 0.0002) of CD14highCD16+ subtype; a concomitant re-
duction in the proportion (from a median of 91 to 86%; P ¼ 0004)
and cell count (from a median of 443.90 to 399.00 cells/mL; P ¼
0.002) of classical CD14highCD162 monocytes was noted; no change
in the non-classical CD14lowCD16+ population was observed
(Figure 3).
Treatment with all of the tested anti-platelet regimes counteracted
the changes in monocyte phenotype induced by vaccination. Although
no statistically significant differences were observed among the treated
groups, aspirin 300 mg exerted the strongest effect in limiting the ex-
pansion of CD14highCD16+ count post-vaccination (median percent-
age increase from baseline was 212.6 in Group 1 vs. +67.3 in
untreated; P ¼ 0.001). Attenuation in the CD14highCD16+ increase
post-vaccination was also observed in Group 2 (aspirin 75 mg) (median
percentage increase was 9.3; P ¼ 0.002 vs. untreated) and, although
less pronounced, in Group 3 (clopidogrel) (median percentage in-
crease was 10.8; P ¼ 0.002 vs. untreated).
The results were confirmed when CD16 expression, specifically ana-
lysed within the CD14high population, was studied using the nMFI strat-
egy. Group 4 (untreated) showed a significant rise in monocytic CD16
levels post-vaccination (median percentage change from baseline was
+20.92; P ¼ 0.002 vs. baseline) that was abolished by all anti-platelet
drugs, with aspirin 300 mg being the most efficacious among treat-
ments (median percentage increase from baseline in Group 1 was
22.1; P ¼ 0.006 vs. Group 4; in Groups 2 and 3, it was +0.5 and
+2, respectively; P ¼ 0.02 vs. untreated for both comparison). Like-
wise, a strong direct correlation was found between the increase
from baseline of CD14highCD16+ cell count and CD16 nMFI (r ¼
0.5; P ¼ 0.0004) (Figure 3). While attenuating the increase in
CD14highCD16+ cells, the anti-platelet regimes counteracted the re-
duction in CD14highCD162 monocytes observed in untreated partici-
pants post-vaccination (Figure 3). The two monocyte subsets showed a
strong inverse correlation with one another (r ¼ 20.8; P, 0.0001).
3.3 Modulation of P-selectin is linearly
related to the change in monocyte
phenotype
The level of P-selectin post-immunization in Group 4 increased by a
median of +17.2% (P ¼ 0.039 vs. baseline) (Figure 4). A significant de-
crease in P-selectin was observed in participants on aspirin 300 mg
(median percentage change from baseline was 230.7% in Group 1;
P ¼ 0.003 vs. baseline and P ¼ 0.007 vs. untreated) and aspirin 75 mg
(234.7% in Group 2; P ¼ 0.011 vs. baseline and P ¼ 0.002 vs. untreat-
ed). Treatment with clopidogrel led to a median change from baseline
of P-selectin of 3.3% (P ¼ 0.463 vs. baseline and P ¼ 0.388 vs. untreat-
ed). In a combined Spearman’s correlation analysis incorporating all
study variables, monocyte phenotype changes correlated only with
changes in P-selectin. Indeed, the increase in P-selectin values was
directly correlated with an increase in CD14highCD16+ cell count
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Table 1 Baseline characteristics of the study population
Group 1 (aspirin 300 mg) Group 2 (aspirin 75 mg) Group 3 (clopidogrel) Group 4 (placebo)
Gender (n) 4 male 3 male 5 male 6 male
11 female 12 female 10 female 9 female
Age (years) 32.00 (30.00–35.25) 33.50 (28.75–41.25) 36.00 (31.5–43.50) 37.00 (31.00–43.50)
SBP/DBP (mmHg) 117+4/78+2 121+5/82+3 123+4/84+2 125+6/81+4
Smokers (current) (n) 2 3 2 1
BMI (kg/m2) 22.78 (20.81–26.00) 25.23 (21.87–28.47) 25.12 (20.61–28.42) 23.63 (21.83–28.66)
HDL cholesterol (mmol/L) 1.872+0.08 1.751+0.10 1.735+0.09 1.793+0.09
LDL cholesterol (mmol/L) 2.74 (2.42–3.33) 2.87 (2.43–3.43) 2.49 (2.24–3.15) 2.20 (1.77–3.03)
Triglycerides (mmol/L) 1.08 (0.72–1.32) 1.00 (0.80–1.39) 1.07 (0.81–1.50) 0.93 (0.69–2.04)
Leucocytes (cells × 109/L) 5.99+0.31 6.01+0.33 6.13+0.38 6.23+0.27
Monocytes (cells × 109/L) 0.5 (0.4–0.5) 0.5 (0.4–0.5) 0.4 (0.3–0.5) 0.5 (0.4–0.625)
Platelets (×109/L) 219.5 (190.3–240.8) 211.0 (184.0–240.0) 228.0 (204.0–251.0) 219.5 (171.3–248.8)
HbA1c (mmol/mol) 32.50 (30.75–36.00) 32.00 (29.75–34.00) 33.00 (31.00–34.00) 34 (31.00–36.00)
Creatinine (mmol/L) 73.53+2.72 70.07+3.27 72.79+3.17 73.10+3.54
Values are expressed as the mean+ SEM or median (IQR).
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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(r ¼ 0.5; P ¼ 0.0002) and a reduction in CD14highCD162 absolute
number (r ¼ 20.4; P ¼ 0.001) (Figure 4). No relationships emerged be-
tween P-selectin and any of the other variables analysed in the study
population.
4. Discussion
Atheroma development in humans is accompanied by systemic im-
munological abnormalities that share homologies with autoimmune
diseases.17 In a pathophysiological model of atherosclerosis, the key
contributing factors can be grouped into three main phases: (i) accumu-
lation within the artery and in blood of immunogenic self-proteins, i.e.
oxidized low-density lipoprotein derived from exposure to cardiovas-
cular risk factors; (ii) consequent activation of innate immune media-
tors (primarily myeloid cells, but recent findings also point towards
platelets playing a crucial role) through engagement of pattern recog-
nition receptors; and (iii) a subsequent adaptive immunological re-
sponse involving T and B cells.18 In this context, the influenza
immunization provides a valuable experimental model to study the
dynamics of monocyte phenotype in response to an immunogenic
stimulus. In keeping with a previous study by this group,9 the current
data confirm that immunization administration generates a reduction
in the proportion of “classical” CD14highCD162 monocytes, which
mirrors the increase in the ‘intermediate’ CD14highCD16+ subset in
peripheral blood samples from the untreated participants. This shift
in the profile of circulating monocytes towards a CD16+ phenotype
mimics the inflammatory response that characterizes atherosclerotic
patients.2– 8 Whether this event has functional implications in disease
progression remains unclear. It is worth mentioning, however, that
CD16 is an important signalling molecule with a relevant role in the
innate response to immunogenic stimuli, in light of its demonstrated
involvement in the phagocytosis of immunoglobulin type G (IgG)-
opsonized external particles by myeloid cell types that subsequently
stimulates the adaptive immune system.19,20 Of note, polymorphism
of CD16A, which is specifically expressed on monocytes, has been
reported to influence susceptibility to, as well as severity of, coronary
disease.21 Indeed, CD16A genetic variants confer distinct affinity for
IgG molecules with consequent effects on the efficiency of clearance
Figure 2 Anti-platelet drugs do not affect high-sensitivity C-reactive protein rise post-vaccination. The absolute values for high-sensitivity C-reactive
protein (A), IL-6 (B), IL-1b (C), and TNF-a (D) at baseline and post-vaccination are shown. Data are reported as median with IQR. P-values were calcu-
lated using Wilcoxon matched-pairs signed-rank test for post-vaccination vs. baseline comparison within groups; rank ANCOVA was used for
between-group comparison and identified no significant differences.
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Figure 3 Anti-platelet drugs counteract CD14highCD16+ expansion induced by vaccination. The percentage change from baseline of
CD14highCD162, CD14highCD16+, and CD14lowCD16+ cell count in each of the groups is reported in A, B, and C, respectively, with the absolute values
at baseline and post-vaccination shown in the table (P-values were calculated using rank ANCOVA). Also shown is the prevalence of each monocyte
subset (expressed as percentage over total monocytes) at baseline and post-vaccination in the different groups (E, F, and G). Graphs D and H show the
correlation between percentage change in CD14highCD16+ cell count and CD16 nMFI (on the top) and between CD14highCD16+ and CD14highCD162
cell count (on the bottom). Values are reported as median and IQR. *P ¼ 0.002; **P ¼ 0.0002 vs. baseline within Group 4 using Wilcoxon matched-pairs
signed-rank test.
Figure 4 Modulation of P-selectin correlates with change in monocyte phenotype. The table shows the P-selectin values at baseline and post-
vaccination stratified among groups, with P-values calculated using rank ANCOVA. Percentage change from baseline of P-selectin in each group is shown
in graph A. B and C report the correlation between change in P-selectin and change in classical CD14highCD162 and intermediate CD14highCD16+
monocyte cell count, respectively. Values are reported as median and IQR. *P ¼ 0.003; **P ¼ 0.011; ***P ¼ 0.039 vs. baseline within groups using Wil-
coxon matched-pairs signed-rank test.
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of circulating immunogenic/pro-atherogenic factors that would other-
wise accumulate within the arterial wall to perpetuate inflammation.21
On this background, an increase in circulating CD14highCD16+ mono-
cytes should be regarded as a protective anti-atherogenic mechanism.
On the other hand, ‘intermediate’ monocytes are known to more easily
infiltrate the arterial wall compared with the ‘classical’ CD14highCD162
cells,9 thus suggesting a detrimental effect. However, in order to test
the pro-atherogenic relevance of ‘intermediate’ monocytes in human
disease, interventional clinical trials in cardiovascular patients would
need to be conducted to establish whether therapeutic modulation
of circulating monocyte profile impacts on plaque progression. To
our knowledge, no such studies have been conducted to date. Our
findings are the first to show a therapeutic modulation of the pheno-
type of circulating monocytes induced by therapies conventionally
used in primary and secondary prevention of cardiovascular disease,
whose potential effect on plaque progression would therefore merit
consideration in future clinical trials.
In our study, all the tested anti-platelet regimes, including the COX-
inhibitor, aspirin, used at high (300 mg) and low (75 mg) doses, and the
P2Y12 antagonist clopidogrel were able to attenuate the expansion of
‘intermediate’ monocytes in the peripheral blood following vaccination.
However, a different efficacy among treatments was noted in the
modulation of the phenotype of circulating monocytes that was found
to be linearly correlated with their effectiveness in reducing soluble
P-selectin.
We have previously shown that expression of P-selectin on activated
platelets and the consequent formation of monocyte–platelet aggre-
gates (MPA) is a key event in the acquisition of a CD16+ profile by cir-
culating monocytes.9 In the current study, we did not perform MPA
measurement due to technical limitations. Indeed, while the monocytic
phenotype remains stable in blood collected in EDTA tubes for up to
4 h since venepuncture,22 immediate blood processing is required for a
reliable assessment of MPA in citrated plasma that is not affected by in
vitro platelet activation.23 In this study, plasma separation could be per-
formed soon after blood sampling, while the staining for flow cyto-
metric assays was delayed by 30 min following venepuncture.
Hence, soluble P-selectin was chosen as a platelet marker to provide
a more reliable evaluation of platelet activity and an indirect measure
of monocyte–platelet interaction, particularly in consideration of our
prior in vitro experiments that showed a significant rise in soluble
P-selectin during MPA formation9 and recent clinical evidence describ-
ing a significant contribution of soluble P-selectin to MPA formation
in vivo.24
The different effects observed among treatments on the level of
P-selectin, particularly between the two aspirin groups and clopidogrel,
might be attributed to either a different pharmacological target, i.e.
COX-inhibition vs. P2Y12 antagonism, or different pharmacokinetics.
Indeed, aspirin achieves a dose-dependent maximum platelet inhibition
within 2 h post-loading dose while clopidogrel requires 5 h to reach a
steady state and a level of platelet inhibition of 60% only following a
loading dose of 300 mg.25 These differences might have played a critical
role particularly in a short-term study such as this. As regards the two
different groups of aspirin, the slight superiority of the 300 mg dose
might be ascribed to the dose-dependent inhibition of COX-activity
with a consequent anti-inflammatory action that for low doses of as-
pirin (75 mg) is negligible.26 However, aspirin 300 mg did not modify
the inflammatory biomarkers measured in this study, consistent with
early evidence demonstrating a clinically relevant anti-inflammatory ef-
fect of aspirin occurring at doses of 1 g or greater.27 Overall, this
evidence points towards platelet inhibition as the main determinant
in the observed results, which is particularly supported by the direct
relationship found between amplitude in P-selectin reduction and
change in monocyte phenotype in response to anti-platelet therapy.
Similarity between the two groups of aspirin appears of particular
relevance in light of the fact that aspirin 75 mg is the dose currently
recommended for cardiovascular prevention, and no superior anti-
thrombotic efficacy has been reported for aspirin 300 mg.28 –33
The lack of activity of anti-platelet therapy on the non-specific
marker of inflammation, high-sensitivity C-reactive protein, suggests a
targeted immunomodulatory action. Regarding production of
pro-inflammatory cytokines, the phenotype of circulating monocytes
did not influence the levels of TNF-a, IL-6, and IL-1b in our study par-
ticipants, at least when measured 48 h post-immunization. There were
no significant differences between their baseline and post-
immunization values in any of the groups. This is consistent with previ-
ously published reports showing an increase in high-sensitivity
C-reactive protein in healthy subjects 2 days after influenza immuniza-
tion that can be partly ascribed to an early rise in IL-6, but not TNF-a, 1
day post-vaccination.34,35 We cannot exclude, therefore, a change in le-
vels of inflammatory cytokines among groups at time points other than
those considered in the current study. Also, the effect of treatment on
monocyte distribution was not analysed beyond the 48 h post-
immunization; thus, the total duration of this effect remains to be
established.
In conclusion, we have demonstrated in this proof-of-concept study
that anti-platelet therapy can attenuate the development of a CD16+
profile by circulating monocytes under pro-inflammatory conditions.
Modulation of P-selectin levels seems to be critical in determining
the extent of this pharmacological action on monocytes, possibly linked
to an interference in MPA formation; however, this remains to be con-
firmed. Further work is needed to better understand the underlying
biomechanistics. Indeed, a limitation of this study was the lack of inclu-
sion of additional platelet biomarkers and functional assays. These may
have highlighted modulatory actions of anti-platelet drugs on specific
platelet-dependent pathways. The relationship found between
P-selectin levels and monocyte phenotype could merely reflect effect-
iveness of platelet inhibition without this biomarker, necessarily repre-
senting a mediator of change in monocyte phenotype. More
importantly, further research is needed to clarify whether a similar
therapeutic effect is exerted by anti-platelet therapy in cardiovascular
patients and to ascertain its implication in atherosclerosis progression.
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